Intas' MD On Acquiring Best-Performing Assets And Brexit

India's largest privately held pharmaceutical company, Intas, says that it understands Europe well and that the best-performing assets acquired from Teva there are a "perfect fit" for its business. Intas vice chair and managing director Binish Chudgar spoke to Scrip on the buyout and why Brexit isn't a major concern - at least for now.

For the low-profile Intas Pharmaceuticals Ltd., buying the assets and operations of Actavis Generics in the UK and Ireland for £603m is a big deal, quite literally.

But vice chair and managing director Binish Chudgar was measured and downplayed any excessive excitement around the buyout. Chudgar said that the Ahmedabad-based Intas would remain a generally "silent" company,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Scrip

GSK’s Nucala Set For Dupixent Face-Off After FDA COPD Nod

 
• By 

The UK major's asthma drug gets a key expanded approval.

Merus Bispecific Impresses In Head And Neck Cancer

 

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Zydus To Continue Mirabegron Sales, Looks To World-First Dual Shigella-Typhoid Vaccine

 
• By 

Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list